Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Breast Cancer Res Treat. 2013 Oct 19;142(2):10.1007/s10549-013-2725-5. doi: 10.1007/s10549-013-2725-5

Fig. 2.

Fig. 2

Landmark analyses at 1, 2, and 3 years after lobular carcinoma in situ (LCIS) diagnosis. a Rate of cancer detection among patients having an MRI within the first year following LCIS diagnosis (red line, median follow-up 44.67 months; range 3.57–121.93 months) versus those not having an MRI during the first year or never having an MRI (blue line, median follow-up, 49.87 months; range 0.16–139 months. b Rate of cancer detection among patients having an MRI within the first 2 years following LCIS diagnosis (red line, median follow-up, 36.59 months; range 0.07–120.39 months) versus those not having an MRI during the first 2 years or never having an MRI (blue line, median follow-up 49.08 months; range 0.07–127.4 months). c Rate of cancer detection among patients having an MRI during the first 3 years following LCIS diagnosis (red line, median follow-up 31.8 months; range 0.07–108.39 months) versus those not having an MRI during the first 3 years or never having an MRI (blue line, median follow-up 49.8 months; range 0.16–115.44 months). For each analyses, patients who were lost to follow-up or developed cancer before the landmark time and those taking chemoprevention were excluded